332 related articles for article (PubMed ID: 19519447)
21. Interleukin-6: A Masterplayer in the Cytokine Network.
Uciechowski P; Dempke WCM
Oncology; 2020; 98(3):131-137. PubMed ID: 31958792
[TBL] [Abstract][Full Text] [Related]
22. Function and proteolytic generation of the soluble interleukin-6 receptor in health and disease.
Schumertl T; Lokau J; Rose-John S; Garbers C
Biochim Biophys Acta Mol Cell Res; 2022 Jan; 1869(1):119143. PubMed ID: 34626681
[TBL] [Abstract][Full Text] [Related]
23. The role of interleukin-6 signaling in nervous tissue.
Rothaug M; Becker-Pauly C; Rose-John S
Biochim Biophys Acta; 2016 Jun; 1863(6 Pt A):1218-27. PubMed ID: 27016501
[TBL] [Abstract][Full Text] [Related]
24. Blocking only the bad side of IL-6 in inflammation and cancer.
Rose-John S
Cytokine; 2021 Dec; 148():155690. PubMed ID: 34474215
[TBL] [Abstract][Full Text] [Related]
25. The soluble Interleukin 6 receptor: generation and role in inflammation and cancer.
Chalaris A; Garbers C; Rabe B; Rose-John S; Scheller J
Eur J Cell Biol; 2011; 90(6-7):484-94. PubMed ID: 21145125
[TBL] [Abstract][Full Text] [Related]
26. Dissecting Interleukin-6 Classic and Trans-signaling in Inflammation and Cancer.
Garbers C; Rose-John S
Methods Mol Biol; 2023; 2691():207-224. PubMed ID: 37355548
[TBL] [Abstract][Full Text] [Related]
27. IL-6 transsignaling: the in vivo consequences.
Jones SA; Richards PJ; Scheller J; Rose-John S
J Interferon Cytokine Res; 2005 May; 25(5):241-53. PubMed ID: 15871661
[TBL] [Abstract][Full Text] [Related]
28. Interleukin-6--a key regulator of colorectal cancer development.
Waldner MJ; Foersch S; Neurath MF
Int J Biol Sci; 2012; 8(9):1248-53. PubMed ID: 23136553
[TBL] [Abstract][Full Text] [Related]
29. The role of transsignalling via the agonistic soluble IL-6 receptor in human diseases.
Kallen KJ
Biochim Biophys Acta; 2002 Nov; 1592(3):323-43. PubMed ID: 12421676
[TBL] [Abstract][Full Text] [Related]
30. Role of the IL-6 classic- and trans-signaling pathways in corneal sterile inflammation and wound healing.
Ebihara N; Matsuda A; Nakamura S; Matsuda H; Murakami A
Invest Ophthalmol Vis Sci; 2011 Nov; 52(12):8549-57. PubMed ID: 21989726
[TBL] [Abstract][Full Text] [Related]
31. Soluble gp130 is the natural inhibitor of soluble interleukin-6 receptor transsignaling responses.
Jostock T; Müllberg J; Ozbek S; Atreya R; Blinn G; Voltz N; Fischer M; Neurath MF; Rose-John S
Eur J Biochem; 2001 Jan; 268(1):160-7. PubMed ID: 11121117
[TBL] [Abstract][Full Text] [Related]
32. The regenerative activity of interleukin-6.
Galun E; Rose-John S
Methods Mol Biol; 2013; 982():59-77. PubMed ID: 23456862
[TBL] [Abstract][Full Text] [Related]
33. Effects of blockade of peripheral interleukin-6 trans-signaling on hippocampus-dependent and independent memory in mice.
Braun O; Dewitz C; Möller-Hackbarth K; Scheller J; Schiffelholz T; Baier PC; Rose-John S
J Interferon Cytokine Res; 2013 May; 33(5):254-60. PubMed ID: 23215755
[TBL] [Abstract][Full Text] [Related]
34. Essential role of neutrophil mobilization in concanavalin A-induced hepatitis is based on classic IL-6 signaling but not on IL-6 trans-signaling.
Malchow S; Thaiss W; Jänner N; Waetzig GH; Gewiese-Rabsch J; Garbers C; Yamamoto K; Rose-John S; Scheller J
Biochim Biophys Acta; 2011 Mar; 1812(3):290-301. PubMed ID: 21130161
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of interleukin-6 and its soluble receptor components sIL-6R and sgp130 as markers of inflammation in inflammatory bowel diseases.
Nikolaus S; Waetzig GH; Butzin S; Ziolkiewicz M; Al-Massad N; Thieme F; Lövgren U; Rasmussen BB; Reinheimer TM; Seegert D; Rosenstiel P; Szymczak S; Schreiber S
Int J Colorectal Dis; 2018 Jul; 33(7):927-936. PubMed ID: 29748708
[TBL] [Abstract][Full Text] [Related]
36. Impact of interleukin-6 classic- and trans-signaling on liver damage and regeneration.
Drucker C; Gewiese J; Malchow S; Scheller J; Rose-John S
J Autoimmun; 2010 Feb; 34(1):29-37. PubMed ID: 19717281
[TBL] [Abstract][Full Text] [Related]
37. Generation of Soluble Interleukin-11 and Interleukin-6 Receptors: A Crucial Function for Proteases during Inflammation.
Lokau J; Agthe M; Garbers C
Mediators Inflamm; 2016; 2016():1785021. PubMed ID: 27493449
[TBL] [Abstract][Full Text] [Related]
38. Targeting classical IL-6 signalling or IL-6 trans-signalling in depression?
Maes M; Anderson G; Kubera M; Berk M
Expert Opin Ther Targets; 2014 May; 18(5):495-512. PubMed ID: 24548241
[TBL] [Abstract][Full Text] [Related]
39. IL-6/IL-6 receptor system and its role in physiological and pathological conditions.
Mihara M; Hashizume M; Yoshida H; Suzuki M; Shiina M
Clin Sci (Lond); 2012 Feb; 122(4):143-59. PubMed ID: 22029668
[TBL] [Abstract][Full Text] [Related]
40. Targeting IL-6 trans-signalling: past, present and future prospects.
Rose-John S; Jenkins BJ; Garbers C; Moll JM; Scheller J
Nat Rev Immunol; 2023 Oct; 23(10):666-681. PubMed ID: 37069261
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
